CSF1R and neoplasm: used the brain-permeable sotuletinib (BLZ945) CSF-1R inhibitor in pretreatment models of hematogenous MDA-MB-231-BrM triple-negative and 99LN-BrM luminal B (estrogen receptor positive, HER2 overexpressed) brain metastasis models, which altered microglial localization away from tumor cells and extended survival [24].